Q1: A decent start to the year
13/05/22 -"Lundbeck has started the year on a decent note. While sales declined in constant currency terms, this had largely been expected due to Northera’s patent expiry. Encouragingly, substantial growth ..."
Pages
51
Language
English
Published on
13/05/22
You may also be interested by these reports :
08/12/25
Despite US tariff threats, drug pricing pressures and the persistent insistence from the US government to reshore manufacturing, the AV Big Pharmas ...
05/12/25
Against the backdrop of strong execution, with two outlook upgrades in 2025, backed by vigorous growth across all its focus areas (oncology, ...
28/11/25
Novo’s investors losing more weight than its patients
25/11/25
CureVac’s Q3 sales surpassed market expectations, driven by a one-off contribution from GSK. The operating profit benefited from the resolution of ...